In summary, our report has demonstrated a novel observation that overexpression of RUNDC3A and SNAP25 modulates AKT protein stability to enhance tumour growth and chemoresistance in NECs, which suggests that this novel RUNDC3A/SNAP25/AKT axis may be a potential therapeutic target in patients with NECs. Here, SNAP25 is linked to neoplasm.